Description

Clustered Regularly Interspaced Short Palindromic Repeats, or more popularly “CRISPR”, is a simple yet powerful genome editing technique that has recently taken the scientific community by storm. When coupled with the Cas9 protein, the technology allows for specific changes (addition, modification and deletions) to be made to the DNA of humans, animals, and plants, thereby offering a tremendous amount of potential in a wide array of applications ranging from agriculture biotechnology to therapeutics.

Cas9 variants have become an important means by which suppliers differentiate themselves from each other. Furthermore, because of the nascent nature of the technology, numerous variations on the CRISPR/Cas9 system are likely still waiting to be developed and patented, leaving the door open for suppliers to broaden their CRISPR/Cas9 product offerings. Consequently, the genome editing market, of which CRISPR/Cas9 already accounts for more than half, is poised to expand rapidly over the coming years. By 2021, the market for CRISPR/Cas9 is expected to reach $3.61 billion in annual revenue.

The majority of research scientists rely on the products and services of AddGene, Integrated DNA Technologies (IDT) and Thermo Fisher Scientific for their CRISPR/Cas9 research. However, the market is extremely fragmented, with numerous smaller companies vying for market share. More than 50% of the market is comprised of companies that hold only 8% or less market share.

For both current market leaders and newer startups, nothing is guaranteed. On average, scientists use two to three supplier brands in their laboratories, and a fifth of our respondents said they were highly likely to switch away from their current primary brand in the near future. For companies who produce CRISPR/Cas9 products or provide CRISPR/Cas9 services, this rapid market growth and fluctuation of brand loyalty present a unique opportunity to expand your consumer base by successfully satisfying their needs for effective, quality products and services.

The 2017 Market for CRISPR/Cas9 Genome Editing Products is BioInformatics’ third report on this subject. With such a wide range of potential applications and a still-evolving market of suppliers, let us be a strategic guide to your brand and its competition in this quickly growing market.

Please download the complimentary Report Brochure (upper left corner of your screen) to review the detailed objectives, table of contents, and sample data.

For additional questions, please contact:

Marketing
BioInformatics LLC
703.778.3080 x19
reports@gene2drug.com